CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Krystal Biotech, Inc. - KRYS CFD

    103.36
    0.33%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.33
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026346 %
    Charges from full value of position ($-5.01)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026346%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004124 %
    Charges from full value of position ($0.78)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004124%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Krystal Biotech Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 103.8
    Open* 104.45
    1-Year Change* 38.05%
    Day's Range* 102.89 - 105.08
    52 wk Range 69.81-132.68
    Average Volume (10 days) 376.62K
    Average Volume (3 months) 6.54M
    Market Cap 2.86B
    P/E Ratio -100.00K
    Shares Outstanding 28.21M
    Revenue 8.56M
    EPS -1.46
    Dividend (Yield %) N/A
    Beta 0.83
    Next Earnings Date Feb 26, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 5, 2023 103.80 0.92 0.89% 102.88 104.96 101.38
    Dec 4, 2023 104.68 -0.44 -0.42% 105.12 106.22 103.51
    Dec 1, 2023 106.04 1.93 1.85% 104.11 106.13 101.06
    Nov 30, 2023 104.15 3.72 3.70% 100.43 105.74 100.43
    Nov 29, 2023 100.25 0.31 0.31% 99.94 103.08 99.93
    Nov 28, 2023 100.81 1.67 1.68% 99.14 101.43 98.13
    Nov 27, 2023 100.50 -1.95 -1.90% 102.45 103.38 99.59
    Nov 24, 2023 102.38 0.43 0.42% 101.95 103.74 101.50
    Nov 22, 2023 101.88 0.70 0.69% 101.18 102.91 100.15
    Nov 21, 2023 101.17 -1.72 -1.67% 102.89 104.18 99.93
    Nov 20, 2023 104.71 -1.01 -0.96% 105.72 107.04 103.93
    Nov 17, 2023 104.09 6.21 6.34% 97.88 104.14 96.73
    Nov 16, 2023 98.18 -1.31 -1.32% 99.49 99.79 96.66
    Nov 15, 2023 99.49 -1.45 -1.44% 100.94 103.53 98.93
    Nov 14, 2023 102.71 1.11 1.09% 101.60 104.98 101.60
    Nov 13, 2023 99.57 4.89 5.16% 94.68 100.32 94.68
    Nov 10, 2023 98.47 2.67 2.79% 95.80 98.92 93.63
    Nov 9, 2023 95.88 -5.69 -5.60% 101.57 101.60 95.73
    Nov 8, 2023 102.17 -6.00 -5.55% 108.17 108.17 101.44
    Nov 7, 2023 108.96 5.20 5.01% 103.76 109.46 103.43

    Krystal Biotech, Inc. Events

    Time (UTC) Country Event
    Monday, February 26, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 Krystal Biotech Inc Earnings Release
    Q4 2023 Krystal Biotech Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0 0
    Revenue
    Total Operating Expense 145.196 68.275 32.999 22.081 11.916
    Selling/General/Admin. Expenses, Total 77.735 40.391 15.063 6.465 4.155
    Research & Development 42.461 27.884 17.936 15.616 7.761
    Operating Income -145.196 -68.275 -32.999 -22.081 -11.916
    Interest Income (Expense), Net Non-Operating 5.221 -1.295 0.832 2.993 1.027
    Net Income Before Taxes -139.975 -69.57 -32.167 -19.088 -10.889
    Net Income After Taxes -139.975 -69.57 -32.167 -19.088 -10.889
    Net Income Before Extra. Items -139.975 -69.57 -32.167 -19.088 -10.889
    Net Income -139.975 -69.57 -32.167 -19.088 -10.889
    Income Available to Common Excl. Extra. Items -139.975 -69.57 -32.167 -19.088 -10.889
    Income Available to Common Incl. Extra. Items -139.975 -69.57 -32.167 -19.088 -10.889
    Dilution Adjustment
    Diluted Net Income -139.975 -69.57 -32.167 -19.088 -10.889
    Diluted Weighted Average Shares 25.4917 22.1968 18.7872 15.9011 11.2031
    Diluted EPS Excluding Extraordinary Items -5.491 -3.13423 -1.71218 -1.20042 -0.97196
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS -4.51029 -3.13423 -1.71218 -1.20042 -0.97196
    Total Extraordinary Items 0
    Total Adjustments to Net Income 0
    Unusual Expense (Income) 25
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Total Operating Expense 38.048 48.823 34.771 31.451 28.753
    Selling/General/Admin. Expenses, Total 25.904 24.035 24.03 19.935 17.863
    Research & Development 12.144 12.288 10.741 11.516 10.89
    Operating Income -38.048 -48.823 -34.771 -31.451 -28.753
    Interest Income (Expense), Net Non-Operating 4.838 3.526 2.719 1.601 0.645
    Net Income Before Taxes -33.21 -45.297 -32.052 -29.85 -28.108
    Net Income After Taxes -33.21 -45.297 -32.052 -29.85 -28.108
    Net Income Before Extra. Items -33.21 -45.297 -32.052 -29.85 -28.108
    Net Income -33.21 -45.297 -32.052 -29.85 -28.108
    Income Available to Common Excl. Extra. Items -33.21 -45.297 -32.052 -29.85 -28.108
    Income Available to Common Incl. Extra. Items -33.21 -45.297 -32.052 -29.85 -28.108
    Diluted Net Income -33.21 -45.297 -32.052 -29.85 -28.108
    Diluted Weighted Average Shares 26.6569 25.7122 25.6826 25.6191 25.5452
    Diluted EPS Excluding Extraordinary Items -1.24583 -1.76169 -1.248 -1.16515 -1.10033
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -1.24583 -1.27554 -1.248 -1.16515 -1.10033
    Unusual Expense (Income) 0 12.5 0 0 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 383.779 442.267 275.058 195.88 112.65
    Cash and Short Term Investments 379.171 438.096 271.262 193.685 111.761
    Cash & Equivalents 161.9 341.246 268.269 187.514 103.67
    Prepaid Expenses 4.608 4.171 3.796 2.195 0.889
    Other Current Assets, Total
    Total Assets 558.45 626.295 310.844 209.023 116.116
    Property/Plant/Equipment, Total - Net 169.726 119.583 34.174 11.184 3.014
    Property/Plant/Equipment, Total - Gross 176.519 123.797 36.542 12.034 3.18
    Accumulated Depreciation, Total -6.793 -4.214 -2.368 -0.85 -0.166
    Total Current Liabilities 28.847 25.736 15.452 3.327 2.596
    Accounts Payable 3.981 8.398 2.105 0.724 0.888
    Accrued Expenses 24.556 17.168 5.681 2.544 1.515
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases
    Total Liabilities 36.219 32.719 18.76 6.109 2.89
    Total Long Term Debt 0 0 0 0 0
    Long Term Debt
    Other Liabilities, Total 7.372 6.983 3.308 2.782 0.294
    Total Equity 522.231 593.576 292.084 202.914 113.226
    Redeemable Preferred Stock 0 0
    Common Stock 0.00026 0.003 0.0002 0.00017 0
    Additional Paid-In Capital 803.718 734.523 363.292 241.951 133.183
    Retained Earnings (Accumulated Deficit) -280.759 -140.787 -71.214 -39.047 -19.959
    Total Liabilities & Shareholders’ Equity 558.45 626.295 310.844 209.023 116.116
    Total Common Shares Outstanding 25.7637 25.208 19.7142 17.3543 14.4289
    Other Current Liabilities, Total 0.31 0.17 7.666 0.059 0.193
    Short Term Investments 217.271 96.85 2.993 6.171 8.091
    Other Long Term Assets, Total 0.324 0.074 1.612 1.462 0.452
    Other Equity, Total -0.72826 -0.163 0.0058 0.00983 0.002
    Long Term Investments 4.621 64.371 0 0.497
    Preferred Stock - Non Redeemable, Net 0 0
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 582.128 484.004 355.429 383.779 397.578
    Cash and Short Term Investments 562.069 477.517 350.387 379.171 394.42
    Cash & Equivalents 373.241 275.875 140.745 161.9 186.409
    Short Term Investments 188.828 201.642 209.642 217.271 208.011
    Prepaid Expenses 5.465 6.487 5.042 4.608 3.158
    Total Assets 790.35 684.026 531.847 558.45 576.379
    Property/Plant/Equipment, Total - Net 171.389 171.327 170.887 169.726 166.039
    Property/Plant/Equipment, Total - Gross 182.128 180.471 178.773 176.519 171.84
    Accumulated Depreciation, Total -10.739 -9.144 -7.886 -6.793 -5.801
    Other Long Term Assets, Total 0.285 0.285 0.402 0.324 0.205
    Total Current Liabilities 27.583 23.898 35.076 28.847 28.032
    Accounts Payable 4.34 4.446 4.109 3.981 5.761
    Accrued Expenses 20.776 18.778 30.595 24.556 21.681
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 2.467 0.674 0.372 0.31 0.59
    Total Liabilities 34.402 30.912 42.281 36.219 35.607
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 6.819 7.014 7.205 7.372 7.575
    Total Equity 755.948 653.114 489.566 522.231 540.772
    Preferred Stock - Non Redeemable, Net 0
    Common Stock 0.00028 0.00028 0.00026 0.00026 0.00026
    Additional Paid-In Capital 1034.85 1012.62 815.776 803.718 790.954
    Retained Earnings (Accumulated Deficit) -278.519 -359.266 -326.056 -280.759 -248.707
    Other Equity, Total -0.38228 -0.23628 -0.15426 -0.72826 -1.47526
    Total Liabilities & Shareholders’ Equity 790.35 684.026 531.847 558.45 576.379
    Total Common Shares Outstanding 28.1947 27.9749 25.7962 25.7637 25.7097
    Long Term Investments 36.548 28.41 5.129 4.621 12.557
    Total Receivables, Net 9.316
    Accounts Receivable - Trade, Net 9.316
    Total Inventory 5.278
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -139.975 -69.57 -32.167 -19.088 -10.889
    Cash From Operating Activities -100.569 -47.938 -26.083 -18.69 -9.445
    Cash From Operating Activities 4.055 2.769 1.851 1.09 0.141
    Non-Cash Items 32.54 16.811 3.305 1.306 0.792
    Cash Taxes Paid
    Cash Interest Paid
    Changes in Working Capital 2.811 2.052 0.928 -1.998 0.511
    Cash From Investing Activities -114.083 -226.77 -11.181 -4.991 -10.323
    Capital Expenditures -52.979 -68.336 -14.843 -6.399 -2.234
    Cash From Financing Activities 35.347 347.685 118.019 107.525 73.847
    Issuance (Retirement) of Stock, Net 35.996 355.645 118.019 107.525 73.847
    Issuance (Retirement) of Debt, Net 0
    Net Change in Cash -179.346 72.977 80.755 83.844 54.079
    Other Investing Cash Flow Items, Total -61.104 -158.434 3.662 1.408 -8.089
    Financing Cash Flow Items -0.649 -7.96
    Foreign Exchange Effects -0.041
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -45.297 -139.975 -107.923 -78.073 -49.965
    Cash From Operating Activities -26.156 -100.569 -78.24 -58.552 -15.493
    Cash From Operating Activities 0.705 4.055 2.966 1.991 1.015
    Non-Cash Items 9.832 32.54 23.476 14.453 6.295
    Changes in Working Capital 8.604 2.811 3.241 3.077 27.162
    Cash From Investing Activities 3.563 -114.083 -108.875 -94.132 -55.908
    Capital Expenditures -5.381 -52.979 -47.762 -33.706 -17.191
    Other Investing Cash Flow Items, Total 8.944 -61.104 -61.113 -60.426 -38.717
    Cash From Financing Activities 1.474 35.347 32.278 30.158 -0.542
    Financing Cash Flow Items -0.749 -0.649 -0.649 -0.649 -0.649
    Issuance (Retirement) of Stock, Net 2.223 35.996 32.927 30.807 0.107
    Net Change in Cash -21.155 -179.346 -154.837 -122.526 -71.943
    Foreign Exchange Effects -0.036 -0.041
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Redmile Group, LLC Investment Advisor/Hedge Fund 9.1686 2566661 653381 2023-06-30 LOW
    Avoro Capital Advisors LLC Investment Advisor/Hedge Fund 9.1477 2560811 810811 2023-06-30 LOW
    Fidelity Management & Research Company LLC Investment Advisor 8.9378 2502059 -111213 2023-06-30 LOW
    Krishnan (Krish S) Individual Investor 6.106 1709338 -25000 2023-09-11 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 6.0818 1702554 503610 2023-06-30 LOW
    Krishnan (Suma M) Individual Investor 6.0341 1689206 -25000 2023-09-11 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 5.1634 1445463 -5791 2023-06-30 LOW
    Frazier Healthcare Partners Venture Capital 3.5374 990260 44853 2023-06-30 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 3.2281 903691 -122704 2023-06-30 LOW
    Lord, Abbett & Co. LLC Investment Advisor 3.0101 842648 -118594 2023-06-30 MED
    Point72 Asset Management, L.P. Hedge Fund 1.9978 559261 56861 2023-06-30 HIGH
    Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 1.7382 486597 24507 2023-06-30 LOW
    Credit Suisse Funds AG Investment Advisor/Hedge Fund 1.6604 464818 -168001 2023-06-30 LOW
    Hood River Capital Management LLC Investment Advisor 1.6163 452456 5063 2023-06-30 MED
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.587 444260 13689 2023-06-30 LOW
    Pictet Asset Management Ltd. Investment Advisor/Hedge Fund 1.534 429428 -202965 2023-06-30 LOW
    Nicholas Investment Partners, L.P. Investment Advisor/Hedge Fund 1.3394 374951 233 2023-06-30 MED
    Invus Public Equities Advisors, LLC Investment Advisor 1.2491 349669 -62413 2023-06-30 MED
    T. Rowe Price Associates, Inc. Investment Advisor 1.1221 314110 300652 2023-06-30 LOW
    SEB Investment Management AB Investment Advisor 1.0211 285860 -158 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Krystal Biotech, Inc. Company profile

    About Krystal Biotech Inc

    Krystal Biotech, Inc. is a clinical stage biotechnology company focused on redosable gene delivery for the treatment of serious rare diseases. Using its platform that is based on engineered herpes simplex virus type 1 (HSV-1), the Company create vectors that deliver therapeutic transgenes to cells of interest in multiple organ systems. The Company’s gene therapy product candidates and undertaking preclinical studies and clinical trials of B-VEC, KB105, KB301, KB104, KB407 and KB408. The Company's KB104 is to treat Netherton Syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders associated with thickened scaly skin and characterized by chronic skin inflammation, itchiness, and dehydration.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Krystal Biotech Inc revenues was not reported. Net loss increased from $32.2M to $69.6M. Higher net loss reflects General and Administrative - Balancing increase from $12.8M to $30.2M (expense), Stock-based Compensation in SGA increase from $2.3M to $10.2M (expense), Research and Development - Balancing increase of 44% to $24.5M (expense).

    Industry: Bio Therapeutic Drugs

    2100 Wharton St Ste 701
    PITTSBURGH
    PENNSYLVANIA 15203
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    XRP/USD

    0.64 Price
    +1.460% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    US100

    15,856.20 Price
    -0.080% 1D Chg, %
    Long position overnight fee -0.0263%
    Short position overnight fee 0.0041%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    BTC/USD

    44,119.40 Price
    +0.200% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Gold

    2,030.07 Price
    +0.480% 1D Chg, %
    Long position overnight fee -0.0196%
    Short position overnight fee 0.0114%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading